SRL Diagnostics

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment

Retrieved on: 
Monday, February 12, 2024

The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.

Key Points: 
  • The study, published in the Journal of Clinical Microbiology, titled, “ Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status ,” was conducted at Tufts Medical Center in Boston, Mass.
  • “In this study, the Investigators demonstrated that RaPID/BSI is not prone to false positive results, which is common with assays that rely on sequencing or standard molecular diagnostic techniques.
  • Importantly, they also demonstrated that the assay can detect ongoing infections missed by follow-up cultures.
  • RaPID/BSI correctly identified 58% more ongoing infections in patients with concurrent antimicrobial therapy than follow-up blood cultures.

Cars Commerce Addresses Automotive Retailers' Top Three Pain Points to Help Them Unleash Growth in 2024

Retrieved on: 
Tuesday, January 30, 2024

CHICAGO, Jan. 30, 2024 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS) (d/b/a " Cars Commerce Inc. "), an audience-driven technology company empowering automotive, today shared the top three dealer pain points in 2024 and how the company plans to help its customers solve these challenges to unleash growth.

Key Points: 
  • CHICAGO, Jan. 30, 2024 /PRNewswire/ -- Cars.com Inc. (NYSE: CARS) (d/b/a " Cars Commerce Inc. "), an audience-driven technology company empowering automotive, today shared the top three dealer pain points in 2024 and how the company plans to help its customers solve these challenges to unleash growth.
  • This news comes ahead of the 2024 NADA Show in Las Vegas Feb. 2-4, where dealers and partners can experience the Cars Commerce platform and its connected solutions live in booth #3421W.
  • We built the Cars Commerce platform to solve the connected-commerce conundrum in automotive.
  • Our platform unites the tiers and connects the shopper experience all while reducing complexity for retailers so they can sell more cars more profitably."

FordDirect Selects AccuTrade as its Preferred Vehicle Acquisition and Trade and Appraisal Solution For Its 3000+ U.S. Ford Dealers and Lincoln Retailers to Turn More Cars for More Profit

Retrieved on: 
Wednesday, January 24, 2024

Half of the retailers leveraging the AccuTrade solution in the service drive in 2023 at least doubled their volume of service drive appraisals from January to December².

Key Points: 
  • Half of the retailers leveraging the AccuTrade solution in the service drive in 2023 at least doubled their volume of service drive appraisals from January to December².
  • "FordDirect's mission as a trusted partner and resource to our retailers is to work with the best vendors in the market to support the needs of all Ford Dealers and Lincoln Retailers.
  • "AccuTrade allows dealers to turn vehicle acquisition into a true profit center, ensuring they secure a healthy margin at the point of acquisition with a guaranteed offer backed by Cars Commerce."
  • Ford Dealers and Lincoln Retailers that are interested in learning more about AccuTrade, can visit the Cars Commerce booth (#3421W) at the 2024 NADA Show in Las Vegas Feb. 2-4 or visit www.carscommerce.inc .

Commercial Vehicle ADAS Market to grow by USD 2.52 billion from 2023 to 2028, Aptiv Plc, Autoliv Inc., Brandmotion LLC and more among key companies - Technavio

Retrieved on: 
Friday, December 15, 2023

NEW YORK, Dec. 15, 2023 /PRNewswire/ -- The commercial vehicle adas market is estimated to grow by USD 2.52 billion from 2023 to 2028, growing at a CAGR of 12.39%.

Key Points: 
  • NEW YORK, Dec. 15, 2023 /PRNewswire/ -- The commercial vehicle adas market is estimated to grow by USD 2.52 billion from 2023 to 2028, growing at a CAGR of 12.39%.
  • The commercial vehicle adas market is fragmented owing to the presence of many global and regional companies.
  • Autoliv Inc. - The company offers commercial vehicle ADAS such as driver airbags, side curtain airbags, seatbelts and pyrotechnical safety switches.
  • The commercial vehicle propeller shaft market size is estimated to grow at a CAGR of 4.64% between 2022 and 2027.

ProPharma Launches an Integrated MedTech Organization Providing End-to-End Solutions for Innovators

Retrieved on: 
Thursday, November 16, 2023

RALEIGH, N.C., Nov. 16, 2023 /PRNewswire-PRWeb/ -- ProPharma Group, the world's largest Research Consulting Organization (RCO) and the leading global provider of regulatory, clinical and quality compliance services for the life sciences industry, has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.

Key Points: 
  • ProPharma Group has today launched a new Integrated Global MedTech Practice to provide end-to-end solutions for medical technology companies.
  • "ProPharma's new MedTech practice has extensive experience and offers scalable solutions tailored to client needs, regardless of size or geography" –Dr.
  • The MedTech organization includes Regulatory Strategy, Clinical Strategy and Development, Quality Management and Compliance, Market Access and Reimbursement, and Post Market Surveillance.
  • For more information about ProPharma Group's Global MedTech Practice and its suite of services, please visit https://www.propharmagroup.com/ .

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Retrieved on: 
Thursday, October 26, 2023

The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.

Key Points: 
  • The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.
  • Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay development expertise and robust commercial infrastructure for clinical sample testing.
  • Our partnership aims to accelerate the advancement of cancer companion diagnostics, making them accessible to pharma partners worldwide,” said Jonathan Arnold, Vice President, Head of Translational Science and Precision Diagnostics at QIAGEN.
  • Myriad has provided testing support for hundreds of clinical trials, has obtained 10 companion diagnostic approvals from the FDA and PMDA, and anticipates that the QIAGEN partnership will drive the expansion of the Myriad portfolio of oncology products.

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

Retrieved on: 
Thursday, October 26, 2023

The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.

Key Points: 
  • The alliance between QIAGEN and Myriad brings together the respective strengths of each partner.
  • Myriad leverages its CLIA-certified, CAP-accredited lab platform, assay development expertise and robust commercial infrastructure for clinical sample testing.
  • Our partnership aims to accelerate the advancement of cancer companion diagnostics, making them accessible to pharma partners worldwide,” said Jonathan Arnold, Vice President, Head of Translational Science and Precision Diagnostics at QIAGEN.
  • Myriad has provided testing support for hundreds of clinical trials, has obtained 10 companion diagnostic approvals from the FDA and PMDA, and anticipates that the QIAGEN partnership will drive the expansion of the Myriad portfolio of oncology products.

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.